When administered exogenously, OXM can improve glucose tolerance and result in weight loss, making GLP-1 receptor and glucagon receptor dual agonists a new promising treatment option for patients with diabetes and/or obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.